GlobeNewswire Inc.··Teva Pharmaceutical Industries Ltd.Teva Scales Biosimilars Pipeline with FDA Approval of PONLIMSI, Xolair Candidate Filing
Teva gains FDA approval for denosumab biosimilar PONLIMSI and achieves dual filing acceptance for omalizumab candidate, bolstering its biosimilars portfolio.
AMGNNVSTEVAFDA approvalbiopharmaceutical